For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Most high-income countries ban direct advertising of prescription drugs – why does NZ still allow it?
+News
RESEARCH + FREE READ
Most high-income countries ban direct advertising of prescription drugs – why does NZ still allow it?
Friday 9 August 2024, 03:46 PM

[Image: Towfiqu Barbhui on Unsplash]
David Menkes is an associate professor in Psychological Medicine at the University of Auckland, Waipapa Taumata Rau; Barbara Mintzes is a professor in Pharmaceutical Policy at the School of Pharmacy at Charles Perkins Centre, University of Sydney, and Joel Lexchin is a professor emeritus of Health Policy and Management at York University, Canada
New Zealand and the United States are the only high-income countries to allow unrestricted direct-to-consumer advertising of branded medicines, includ
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.